BioAlliance Pharma SA, the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, announced the launch of its lead product Loramyc on the British, German and Danish markets.
"This simultaneous product launch in three European countries crowns the efforts of our teams and marks another concrete step in the internationalization of our business. In these three countries, we are going to fully leverage our initial experience with the product in France", emphasized Dominique Costantini, BioAlliance Pharma's president and CEO.
"In fact, prescriptions in France grew by 35 per cent at the end of March (relative to the end of December 2007) and June's rate was 60 per cent above the March figure. These progression rates confirm the product's market penetration and its appropriate response to a disease that affects severely ill patients. In France, over 8,000 patients have received a prescription of Loramyc and our goal is to double that figure by the end of this year. The acceleration in prescription rates confirms the product's potential and will be the key element to observe in the UK, Germany and Denmark", added Dominique Costantini.
Loramyc is now available in four European countries and will be commercialized in the UK, Germany and Denmark by SpeBio (a joint venture founded with SpePharm in order to sell the product throughout Europe).
"The SpeBio team is committed to making the product available to private practice and hospital-based oncologists, radiotherapists and infectious disease specialists", stated Jean-François Labbé (CEO of SpeBio). "The product has received a very warm welcome, since it fulfils an unmet medical need in the field of oropharyngeal candidiasis in immunocompromised patients".
With the UK, Germany and Denmark, BioAlliance Pharma is extending its European presence and, with SpeBio, is actively preparing market launches (that could take place before the end of this year) in additional European countries.
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address resistance issues. The company has launched its first portfolio product (Loramyc) in France and already received European Marketing Authorizations in UK, Germany, Belgium, Denmark and Luxemburg. The compound has completed the pivotal Phase III clinical development in oropharyngeal candidiasis in the USA.